Market Cap 182.42M
Revenue (ttm) 0.00
Net Income (ttm) -30.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 336,700
Avg Vol 317,312
Day's Range N/A - N/A
Shares Out 65.86M
Stochastic %K 83%
Beta 0.47
Analysts Sell
Price Target $11.00

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and dev...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 620 3186
Address:
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States
ThomasLD
ThomasLD Jun. 19 at 5:50 PM
$GALT My goal is to reach > $50+ with this stock since Belapectin is the best drug on earth. GLTA!
1 · Reply
SamGantVHee
SamGantVHee Jun. 19 at 4:55 PM
$GALT if yellow line (mid $2.50's) holds, can see $3-4 by July imo. May pull back to red line though (low $2.40's) still need to see a breakout and consolidation over mid $3's to break out of this strong downtrend channel we have been in since the brutal gap down in December have always been a believer that open gaps tend to fill more often than not...and that gap is open from $4.80's to $6.10's of course if we get good news, none of this matters. let's hope for it soon
1 · Reply
Boellie
Boellie Jun. 19 at 7:29 AM
$GALT a big order at close! So someone wants to buy and the other party wants to sell that amount of shares. Correct? So someone is a believer and the other one is a non believer. So it means nothing. Why telling then it a good sign????? Please explain….
2 · Reply
Indibviduate1
Indibviduate1 Jun. 19 at 3:35 AM
$GALT recent fda U turns bode well for accelerated approval for belapectin. UniQure and Replimune have seen an fda u turn after Makary and Prasad’s departure and are looking at accelerated approvals as the regulatory body becomes more open to accepting data
2 · Reply
SamGantVHee
SamGantVHee Jun. 19 at 12:19 AM
3 · Reply
Hegotgame88
Hegotgame88 Jun. 18 at 9:53 PM
0 · Reply
Bobear12
Bobear12 Jun. 18 at 9:12 PM
$GALT $TNXP Ok board spammer. Here is your full momentum read on GALT: WARPLAN ON DEMAND © 🧠 WOD ASK: GALT ❓ Question: Scan GALT and give a summary report. Worth owning at these price levels? Just give me the bottom line. 🕒 2026-06-18T20:14:58.818623+00:00 Bottom line on GALT, tight and tactical: "Not worth a fresh own here—setup is watch only." No system entry here—Sniper is inactive, setup is rated “weak.” Bulls have no real control at 2.825. Momentum Score is 7.2, which puts it at Tier 2—High on the Momentum Scale, but the read is mixed, not explosive. You’ve got immediate support at 2.82 (Volume Weighted Average Price, or VWAP) and a stand-down line just below. If GALT loses 2.82, bears can press down to 2.76 fast. Next support below is thin and risk increases. For bulls, the first job is reclaiming 2.83 (Point of Control, or POC). Real breakout only gets triggered at 2.85–2.88; above that, targets open up at 2.90 and 2.93.
1 · Reply
swardfishtrader
swardfishtrader Jun. 18 at 9:05 PM
$GALT looks like no PR drop, is this a good or bad sign..personally leaning to good sign since I hate end of week news.
4 · Reply
JBRUN
JBRUN Jun. 18 at 8:45 PM
$GALT .....and another 40k in after hours
0 · Reply
kurt2541
kurt2541 Jun. 18 at 8:20 PM
$GALT Does anyone know how 100k shares can be bought at close without moving up price. Would that be a limit MOC order?; or some institutional arrangement with a market maker; or?
7 · Reply
Latest News on GALT
Galectin Therapeutics presents belapectin data at EASL 2026

2026-05-27T15:47:04.000Z - 23 days ago

Galectin Therapeutics presents belapectin data at EASL 2026


Galectin Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

Galectin Therapeutics Quarterly report: Q1 2026


Galectin Therapeutics Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

Galectin Therapeutics Earnings release: Q1 2026


Galectin Therapeutics files $200M mixed securities shelf

2026-03-31T20:17:36.000Z - 2 months ago

Galectin Therapeutics files $200M mixed securities shelf


Galectin Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Galectin Therapeutics Earnings release: Q4 2025


Galectin Therapeutics Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Galectin Therapeutics Annual report: Q4 2025


Galectin Therapeutics appoints Henry Brem to board of directors

2026-03-17T12:15:29.000Z - 3 months ago

Galectin Therapeutics appoints Henry Brem to board of directors


Galectin Therapeutics Transcript: KOL event

Mar 10, 2026, 12:00 PM EDT - 3 months ago

Galectin Therapeutics Transcript: KOL event


Galectin Therapeutics Slides: Corporate presentation

Dec 5, 2025, 6:00 AM EST - 7 months ago

Galectin Therapeutics Slides: Corporate presentation


Galectin Therapeutics Transcript: AGM 2025

Dec 3, 2025, 11:00 AM EST - 7 months ago

Galectin Therapeutics Transcript: AGM 2025


Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year

2025-11-14T13:10:43.000Z - 7 months ago

Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year


Galectin Therapeutics Earnings release: Q3 2025

Nov 14, 2025, 8:00 AM EST - 7 months ago

Galectin Therapeutics Earnings release: Q3 2025


Galectin Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 8:00 AM EST - 7 months ago

Galectin Therapeutics Quarterly report: Q3 2025


Galectin Therapeutics presents NAVIGATE trial results at AASLD

2025-11-10T13:32:14.000Z - 7 months ago

Galectin Therapeutics presents NAVIGATE trial results at AASLD


Galectin Therapeutics Proxy statement: Proxy Filing

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Galectin Therapeutics Proxy statement: Proxy Filing


Galectin Therapeutics Proxy statement: Proxy Filing

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Galectin Therapeutics Proxy statement: Proxy Filing


Galectin Therapeutics Slides: Corporate Presentation

Sep 7, 2025, 6:00 PM EDT - 10 months ago

Galectin Therapeutics Slides: Corporate Presentation


Galectin Therapeutics reports Q2 EPS (12c) vs (20c) last year

2025-08-14T12:11:00.000Z - 11 months ago

Galectin Therapeutics reports Q2 EPS (12c) vs (20c) last year


Galectin Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Galectin Therapeutics Earnings release: Q2 2025


Galectin Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Galectin Therapeutics Quarterly report: Q2 2025


Galectin Therapeutics assumed with a Buy at H.C. Wainwright

2025-06-17T10:05:08.000Z - 1 year ago

Galectin Therapeutics assumed with a Buy at H.C. Wainwright


Galectin Therapeutics Transcript: Study Result

Jun 16, 2025, 12:00 PM EDT - 1 year ago

Galectin Therapeutics Transcript: Study Result


Galectin Therapeutics Press release: Study Result

Jun 16, 2025, 12:00 PM EDT - 1 year ago

Galectin Therapeutics Press release: Study Result


Galectin Therapeutics Slides: Study Result

Jun 16, 2025, 12:00 PM EDT - 1 year ago

Galectin Therapeutics Slides: Study Result


Galectin Therapeutics Earnings release: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Earnings release: Q1 2025


Galectin Therapeutics Quarterly report: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Quarterly report: Q1 2025


Galectin Therapeutics Annual report: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Annual report: Q4 2024


Galectin Therapeutics Earnings release: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Earnings release: Q4 2024


Galectin Therapeutics Proxy statement: Proxy Filing

Dec 3, 2024, 7:00 AM EST - 1 year ago

Galectin Therapeutics Proxy statement: Proxy Filing


Galectin Therapeutics Proxy statement: Proxy Filing

Dec 3, 2024, 7:00 AM EST - 1 year ago

Galectin Therapeutics Proxy statement: Proxy Filing


Galectin Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Galectin Therapeutics Earnings release: Q3 2024


Galectin Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Galectin Therapeutics Quarterly report: Q3 2024


Galectin Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Quarterly report: Q2 2024


Galectin Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Earnings release: Q2 2024


Galectin Therapeutics Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Galectin Therapeutics Quarterly report: Q1 2024


Galectin Therapeutics Earnings release: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Galectin Therapeutics Earnings release: Q1 2024


Galectin Therapeutics Earnings release: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Earnings release: Q4 2023


Galectin Therapeutics Annual report: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Annual report: Q4 2023


Galectin Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Galectin Therapeutics Quarterly report: Q3 2023


Galectin Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Galectin Therapeutics Earnings release: Q3 2023


Galectin Therapeutics Proxy statement: Proxy Filing

Oct 6, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Proxy statement: Proxy Filing


Galectin Therapeutics Proxy statement: Proxy Filing

Oct 6, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Proxy statement: Proxy Filing


Galectin Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Quarterly report: Q2 2023


Galectin Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Earnings release: Q2 2023


Galectin Therapeutics Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Quarterly report: Q1 2023


Galectin Therapeutics Earnings release: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Earnings release: Q1 2023


Galectin Therapeutics Earnings release: Q4 2022

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Earnings release: Q4 2022


Galectin Therapeutics Annual report: Q4 2022

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Galectin Therapeutics Annual report: Q4 2022


Galectin Therapeutics Quarterly report: Q3 2022

Nov 14, 2022, 7:00 AM EST - 3 years ago

Galectin Therapeutics Quarterly report: Q3 2022


Galectin Therapeutics Earnings release: Q3 2022

Nov 14, 2022, 7:00 AM EST - 3 years ago

Galectin Therapeutics Earnings release: Q3 2022


Galectin Therapeutics Proxy statement: Proxy Filing

Oct 17, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Proxy statement: Proxy Filing


Galectin Therapeutics Proxy statement: Proxy Filing

Oct 17, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Proxy statement: Proxy Filing


Galectin Therapeutics to Present in Upcoming Conferences

Oct 14, 2022, 8:00 AM EDT - 4 years ago

Galectin Therapeutics to Present in Upcoming Conferences


Galectin Therapeutics Proxy statement: Proxy Filing

Oct 6, 2022, 8:00 AM EDT - 4 years ago

Galectin Therapeutics Proxy statement: Proxy Filing


ThomasLD
ThomasLD Jun. 19 at 5:50 PM
$GALT My goal is to reach > $50+ with this stock since Belapectin is the best drug on earth. GLTA!
1 · Reply
SamGantVHee
SamGantVHee Jun. 19 at 4:55 PM
$GALT if yellow line (mid $2.50's) holds, can see $3-4 by July imo. May pull back to red line though (low $2.40's) still need to see a breakout and consolidation over mid $3's to break out of this strong downtrend channel we have been in since the brutal gap down in December have always been a believer that open gaps tend to fill more often than not...and that gap is open from $4.80's to $6.10's of course if we get good news, none of this matters. let's hope for it soon
1 · Reply
Boellie
Boellie Jun. 19 at 7:29 AM
$GALT a big order at close! So someone wants to buy and the other party wants to sell that amount of shares. Correct? So someone is a believer and the other one is a non believer. So it means nothing. Why telling then it a good sign????? Please explain….
2 · Reply
Indibviduate1
Indibviduate1 Jun. 19 at 3:35 AM
$GALT recent fda U turns bode well for accelerated approval for belapectin. UniQure and Replimune have seen an fda u turn after Makary and Prasad’s departure and are looking at accelerated approvals as the regulatory body becomes more open to accepting data
2 · Reply
SamGantVHee
SamGantVHee Jun. 19 at 12:19 AM
3 · Reply
Hegotgame88
Hegotgame88 Jun. 18 at 9:53 PM
0 · Reply
Bobear12
Bobear12 Jun. 18 at 9:12 PM
$GALT $TNXP Ok board spammer. Here is your full momentum read on GALT: WARPLAN ON DEMAND © 🧠 WOD ASK: GALT ❓ Question: Scan GALT and give a summary report. Worth owning at these price levels? Just give me the bottom line. 🕒 2026-06-18T20:14:58.818623+00:00 Bottom line on GALT, tight and tactical: "Not worth a fresh own here—setup is watch only." No system entry here—Sniper is inactive, setup is rated “weak.” Bulls have no real control at 2.825. Momentum Score is 7.2, which puts it at Tier 2—High on the Momentum Scale, but the read is mixed, not explosive. You’ve got immediate support at 2.82 (Volume Weighted Average Price, or VWAP) and a stand-down line just below. If GALT loses 2.82, bears can press down to 2.76 fast. Next support below is thin and risk increases. For bulls, the first job is reclaiming 2.83 (Point of Control, or POC). Real breakout only gets triggered at 2.85–2.88; above that, targets open up at 2.90 and 2.93.
1 · Reply
swardfishtrader
swardfishtrader Jun. 18 at 9:05 PM
$GALT looks like no PR drop, is this a good or bad sign..personally leaning to good sign since I hate end of week news.
4 · Reply
JBRUN
JBRUN Jun. 18 at 8:45 PM
$GALT .....and another 40k in after hours
0 · Reply
kurt2541
kurt2541 Jun. 18 at 8:20 PM
$GALT Does anyone know how 100k shares can be bought at close without moving up price. Would that be a limit MOC order?; or some institutional arrangement with a market maker; or?
7 · Reply
Bobear12
Bobear12 Jun. 18 at 8:15 PM
$GALT Did the volume spike again during the afternoon trading? Unusual, before a holiday. Maybe shorts are trying ease out of their positions. Bo
0 · Reply
JBRUN
JBRUN Jun. 18 at 7:48 PM
$GALT market closed tomorrow?
2 · Reply
Bobear12
Bobear12 Jun. 18 at 7:38 PM
$GALT STUCK
0 · Reply
Kilarck
Kilarck Jun. 18 at 6:41 PM
$GALT The shenanigans here will continue as usual. The minutes from type c might be nothing but proceed with phase 3 design. The news that matters is the partnership or AA guidance. These guys might have more data. ;)
0 · Reply
JollyAcorn2021
JollyAcorn2021 Jun. 18 at 6:01 PM
$GALT Its trading nothing like it did in the days before the December 19 crash. Then, it was massive volume and large beta volatility. Today , the last few days, relatively low volume and modest beta, much tighter range. I kind of think that a response of "normal Phase 3, proceed" has been baked into the stock price already. IDK. NFA. GLTA.
1 · Reply
JollyAcorn2021
JollyAcorn2021 Jun. 18 at 4:48 PM
$GALT If we get a PR drop after market on the last trading day before a long week end; well, I wont even look at it. I'll go have a rum and coke or maybe a giant mojito.
1 · Reply
JBRUN
JBRUN Jun. 18 at 4:07 PM
$GALT approaching the 100k mark on volume, could be better
2 · Reply
Indibviduate1
Indibviduate1 Jun. 18 at 3:13 PM
$GALT low low volume and not much else.
0 · Reply
vettebk
vettebk Jun. 18 at 1:53 PM
$GALT only 25K shares and up a dime. Must be having problems locating stock. IBKR reports 68K shares available to short lowest in a few days. Nice day so far.
1 · Reply
JollyAcorn2021
JollyAcorn2021 Jun. 18 at 1:11 PM
$GALT Pre market is DEAD today. Just one weird share. We usually have a couple thousand by now, or at least several hundred shares traded pre-market. Which way will it go?
0 · Reply
ThomasLD
ThomasLD Jun. 18 at 12:51 PM
$GALT Remember Belapectin works + 💯 % ultra safe! Tested with sickest patients and it was successful! FDA wants SAFETY first!!!! I think they have already prepared for partnership/ BO. That way after GALT MANAGEMENT receive a guidance from FDA, they will likely drop the PR including a partnership or BO within 72 hours window to the public. Partnership is needed right away is because the company only has about $10M in the bank. It is not a good idea for Richard to continue to loan money for the company for a short phase 3 study unless he can afford to take that risk. I think AA is coming because FDA is willing to use new policies to approve for AA. FDA GUIDANCE will likely fall in July, 2026. It does not matter how much you want ($$$$) for BO. Richard U and his team will not give Belapectin away for nothing unless FDA don’t approve it. $18B peak Belapectin sales is still in the card with ~ 119 to 126 m OS + dilution. GLTA!
2 · Reply
dubist
dubist Jun. 18 at 12:30 PM
$GALT can someone check with Schwab to see how things are going with Galt?
0 · Reply